Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those without MDD, ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

In this longitudinal cohort study of older drivers, adults with major depressive disorder demonstrated distinct and riskier driving behaviors than those in the control group without depression, with ...

—Major depressive disorder and treatment-resistant depression both require high levels of resources—both clinical and economic—across the spectrum of healthcare settings. A new study from ...

SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...

The diagnosis of major depressive disorder is based on the patient's self-reported experiences, behavior reported by relatives or friends, and a mental status examination. There is no laboratory ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

Sleep problems may be one of the first symptoms of major depressive disorder -- a serious, but treatable mental health problem, more commonly known as depression. Not only a symptom of depression ...